Now showing items 1-8 of 8

    • A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients 

      Seibold, Petra; Schmezer, Peter; Behrens, Sabine; Michailidou, Kyriaki; Bolla, Manjeet K; Wang, Qin; Flesch-Janys, Dieter et al. (2015-12-16)
      Abstract Background Personalized therapy considering clinical and genetic patient characteristics will further improve breast cancer survival. Two widely used treatments, ...
    • Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis 

      Sobral-Leite, Marcelo; Wesseling, Jelle; Smit, Vincent T H B M; Nevanlinna, Heli; van Miltenburg, Martine H; Sanders, Joyce; Hofland, Ingrid et al. (2015-07-02)
      Abstract Background Annexin A1 (ANXA1) is a protein related with the carcinogenesis process and metastasis formation in many tumors. However, little is known about the prognostic ...
    • Annexin A1 expression in breast cancer: tumor subtypes and prognosis 

      Sobral-Leite, Marcelo; Wesseling, Jelle; Smit, Vincent T. H. B. M.; Nevanlinna, Heli; van Miltenburg, Martine H.; Sanders, Joyce; Hofland, Ingrid et al. (BioMed Central, 2015-06-25)
      Background Annexin A1 (ANXA1) is a protein related with the carcinogenesis process and metastasis formation in many tumors. However, little is known about the prognostic value of ANXA1 in breast cancer. The purpose of ...
    • Combined effects of single nucleotide polymorphisms TP53R72P and MDM2SNP309, and p53 expression on survival of breast cancer patients 

      Schmidt, Marjanka K.; Tommiska, Johanna; Broeks, Annegien; van Leeuwen, Flora E.; Van't Veer, Laura J.; Pharoah, Paul D. P.; Easton, Douglas F. et al. (2009-12-18)
      Abstract Introduction Somatic inactivation of the TP53 gene in breast tumors is a marker for poor outcome, and breast cancer outcome might also be affected by germ-line variation in the TP53 gene or its regulators. We ...
    • Genetic variation in the immunosuppression pathway genes and breast cancer: a pooled analysis of 42,510 cases and 40,577 controls from the Breast 

      Lei, Jieping; Rudolph, Anja; Moysich, Kirsten B.; Behrens, Sabine; Goode, Ellen L.; Bolla, Manjeet K.; Dennis, Joe et al. (Springer, 2015-11-30)
      Immunosuppression plays a pivotal role in assisting tumors to evade immune destruction and promoting tumor development. We hypothesized that genetic variation in the immunosuppression pathway genes may be implicated in ...
    • Identification of Novel Genetic Markers of Breast Cancer Survival 

      Guo, Qi; Schmidt, Marjanka K.; Kraft, Peter; Canisius, Sander; Chen, Constance; Khan, Sofia; Tyrer, Jonathan et al. (Oxford Journals, 2015-04-18)
      Background: Survival after a diagnosis of breast cancer varies considerably between patients, and some of this variation may be because of germline genetic variation. We aimed to identify genetic markers associated with ...
    • Patient survival and tumor characteristics associated with $\textit{CHEK2}$:p.I157T – findings from the Breast Cancer Association Consortium 

      Muranen, Taru A.; Blomqvist, Carl; Dörk, Thilo; Jakubowska, Anna; Heikkilä, Päivi; Fagerholm, Rainer; Greco, Dario et al. (BioMed Central, 2016-10-03)
      $\textbf{Background}$ P.I157T is a $\textit{CHEK2}$ missense mutation associated with a modest increase in breast cancer risk. Previously, another $\textit{CHEK2}$ mutation, the protein truncating c.1100delC has been ...
    • Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium 

      Howat, William; Blows, Fiona; Provenzano, Elena; Brook, Mark; Morris, Lorna; Gazinska, Patrycja; Johnson, Nicola et al. (Wiley, 2014-12-04)
      Breast cancer risk factors and clinical outcomes vary by tumor marker expression. However, individual studies often lack the power required to assess these relationships, and large-scale analyses are limited by the need ...